JP2013501071A - リナクロチドを含む処方物 - Google Patents

リナクロチドを含む処方物 Download PDF

Info

Publication number
JP2013501071A
JP2013501071A JP2012523941A JP2012523941A JP2013501071A JP 2013501071 A JP2013501071 A JP 2013501071A JP 2012523941 A JP2012523941 A JP 2012523941A JP 2012523941 A JP2012523941 A JP 2012523941A JP 2013501071 A JP2013501071 A JP 2013501071A
Authority
JP
Japan
Prior art keywords
composition
linaclotide
composition comprises
weight
stabilizing amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012523941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501071A5 (enExample
Inventor
アンジェリカ フレツセン，
スティーブン ウィトウスキー，
アルフレド グロシー，
ホン チャオ，
マヘンドラ デディーヤ，
ユン モー，
Original Assignee
アイロンウッド ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43544939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013501071(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アイロンウッド ファーマシューティカルズ， インコーポレイテッド filed Critical アイロンウッド ファーマシューティカルズ， インコーポレイテッド
Publication of JP2013501071A publication Critical patent/JP2013501071A/ja
Publication of JP2013501071A5 publication Critical patent/JP2013501071A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Mechanical Engineering (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
JP2012523941A 2009-08-06 2010-08-05 リナクロチドを含む処方物 Withdrawn JP2013501071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23172509P 2009-08-06 2009-08-06
US61/231,725 2009-08-06
PCT/US2010/044522 WO2011017502A2 (en) 2009-08-06 2010-08-05 Linaclotide-containing formulations for oral administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015025192A Division JP2015098476A (ja) 2009-08-06 2015-02-12 リナクロチドを含む処方物

Publications (2)

Publication Number Publication Date
JP2013501071A true JP2013501071A (ja) 2013-01-10
JP2013501071A5 JP2013501071A5 (enExample) 2013-09-12

Family

ID=43544939

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012523941A Withdrawn JP2013501071A (ja) 2009-08-06 2010-08-05 リナクロチドを含む処方物
JP2015025192A Pending JP2015098476A (ja) 2009-08-06 2015-02-12 リナクロチドを含む処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015025192A Pending JP2015098476A (ja) 2009-08-06 2015-02-12 リナクロチドを含む処方物

Country Status (5)

Country Link
US (4) US8748573B2 (enExample)
JP (2) JP2013501071A (enExample)
CA (1) CA2770077A1 (enExample)
MX (2) MX2012001660A (enExample)
WO (1) WO2011017502A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531665A (ja) * 2014-10-07 2017-10-26 シプルメット・ゲーエムベーハー ペプチド又はタンパク質薬物を経口送達するための医薬製剤
JP2018529749A (ja) * 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
JP2021113227A (ja) * 2013-12-11 2021-08-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの遅延放出組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60101B1 (sr) * 2008-08-15 2020-05-29 Ironwood Pharmaceuticals Inc Formulacije koje sadrže linaklotid za oralnu primenu
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CA2790213A1 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
ES2763404T3 (es) 2010-08-11 2020-05-28 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
CN104053449B (zh) * 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
WO2015166468A1 (en) * 2014-05-02 2015-11-05 Sinoveda Canada, Inc. Formulas comprising highly soluble elements and vitamin d for the prevention and treatment of bowel conditions during calcium supplementation
US10272131B2 (en) 2014-08-11 2019-04-30 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
WO2016038497A1 (en) * 2014-09-08 2016-03-17 Auro Peptides Ltd A process for the preparation of linaclotide
WO2016125064A1 (en) * 2015-02-02 2016-08-11 Aurobindo Pharma Ltd Stable compositions comprising linaclotide
JP2018516937A (ja) * 2015-06-05 2018-06-28 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの改変または標的放出製剤
TWI795462B (zh) * 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
CN116098864B (zh) * 2023-04-11 2023-06-09 北京普诺旺康医药科技有限公司 一种利那洛肽干混悬剂及其制备方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
JPS63146828A (ja) * 1986-07-18 1988-06-18 Chugai Pharmaceut Co Ltd 安定な顆粒球コロニ−刺激因子含有製剤
JPS6471818A (en) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Storage-stable and tolerable human protein medicine and manufacture
JP2004075682A (ja) * 2002-08-13 2004-03-11 Aventis Behring Gmbh 保存に安定な液体フィブリノゲン製剤
US20050020811A1 (en) * 2003-01-28 2005-01-27 Currie Mark G. Methods and compositions for the treatment of gastrointestinal disorders
JP2005530682A (ja) * 2001-12-21 2005-10-13 ノボ　ノルディスク　アクティーゼルスカブ 修飾第ｖｉｉ因子ポリペプチドの液体組成物
JP2007528842A (ja) * 2003-06-10 2007-10-18 エルジー ライフサイエンス リミテッド 血清アルブミンを含まない、安定なヒトエリスロポエチン水溶液
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
WO2008145989A1 (en) * 2007-05-30 2008-12-04 Nhs Blood And Transplant Methods for preparing factor x, activated factor x, inactivated factor x and inactivated factor xa, and pharmaceutical compositions comprising same
WO2010019266A2 (en) * 2008-08-15 2010-02-18 Ironwood Pharmaceuticals, Inc. Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658973A5 (fr) * 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
CA2028848A1 (en) 1989-04-11 1990-10-12 Tapan Audhya Lyophilized peptide formulations
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) * 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) * 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
BR9710130A (pt) 1996-07-03 1999-08-10 Alza Corp Formulações de peptídeos próticas não-aquosas
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
WO2000004880A1 (en) 1998-07-23 2000-02-03 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
CA2352389C (en) 1998-11-27 2009-01-20 Kanji Takada An oral formulation for gastrointestinal drug delivery
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
CA2413702A1 (en) * 2000-06-28 2002-01-03 Teva Pharmaceuticals Industries Ltd. Carvedilol
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AU2001296389A1 (en) 2000-09-29 2002-04-08 Cognetix, Inc. Stable peptide formulations
WO2002055101A2 (en) 2000-12-21 2002-07-18 Inhale Therapeutic Syst Storage stable powder compositions of interleukin-4 receptor
CA2435835A1 (en) 2001-02-02 2002-08-15 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
GB0104371D0 (en) * 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
WO2002078683A1 (en) 2001-03-29 2002-10-10 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
WO2003014304A2 (en) 2001-08-09 2003-02-20 Doctor's Signature Sales And Marketing International Corp. [(Dba)] Life Force International Protonic formulation
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
CN1726012A (zh) 2002-12-11 2006-01-25 辉瑞产品公司 活性物质在高脂肪环境中的控制释放
BR122018074353B8 (pt) 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DK1638586T3 (da) * 2003-05-14 2008-06-23 Indus Biotech Pvt Ltd Synergistisk sammensætning til behandling af diabetes mellitus
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
PL1644021T3 (pl) 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE102004011663B4 (de) 2004-03-10 2006-04-27 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
WO2006071102A1 (en) 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
EP1940441A4 (en) 2005-08-19 2010-01-27 Ironwood Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
US20090305993A1 (en) 2006-02-24 2009-12-10 Ironwood Pharmaceuticals, Inc. Methods and composition for the treatment of gastrointestinal disorders
ITMI20060629A1 (it) * 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
EP2078529B1 (en) 2006-07-10 2014-12-10 PBA3 Biomed GmbH Antimicrobial peptides
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2059260B1 (en) 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
EP2650303A1 (en) 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010027405A2 (en) 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration
US20120009225A1 (en) 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法
WO2011019819A1 (en) * 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
JPS63146828A (ja) * 1986-07-18 1988-06-18 Chugai Pharmaceut Co Ltd 安定な顆粒球コロニ−刺激因子含有製剤
JPS6471818A (en) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Storage-stable and tolerable human protein medicine and manufacture
JP2005530682A (ja) * 2001-12-21 2005-10-13 ノボ　ノルディスク　アクティーゼルスカブ 修飾第ｖｉｉ因子ポリペプチドの液体組成物
JP2004075682A (ja) * 2002-08-13 2004-03-11 Aventis Behring Gmbh 保存に安定な液体フィブリノゲン製剤
US20050020811A1 (en) * 2003-01-28 2005-01-27 Currie Mark G. Methods and compositions for the treatment of gastrointestinal disorders
JP2007528842A (ja) * 2003-06-10 2007-10-18 エルジー ライフサイエンス リミテッド 血清アルブミンを含まない、安定なヒトエリスロポエチン水溶液
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
WO2008145989A1 (en) * 2007-05-30 2008-12-04 Nhs Blood And Transplant Methods for preparing factor x, activated factor x, inactivated factor x and inactivated factor xa, and pharmaceutical compositions comprising same
WO2010019266A2 (en) * 2008-08-15 2010-02-18 Ironwood Pharmaceuticals, Inc. Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021113227A (ja) * 2013-12-11 2021-08-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの遅延放出組成物
JP7483656B2 (ja) 2013-12-11 2024-05-15 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの遅延放出組成物
JP2017531665A (ja) * 2014-10-07 2017-10-26 シプルメット・ゲーエムベーハー ペプチド又はタンパク質薬物を経口送達するための医薬製剤
JP2018529749A (ja) * 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
US10905744B2 (en) 2015-10-07 2021-02-02 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs

Also Published As

Publication number Publication date
MX2012001660A (es) 2012-03-26
CA2770077A1 (en) 2011-02-10
JP2015098476A (ja) 2015-05-28
WO2011017502A2 (en) 2011-02-10
WO2011017502A3 (en) 2011-05-19
US20130190239A1 (en) 2013-07-25
US20110059903A1 (en) 2011-03-10
US8748573B2 (en) 2014-06-10
US20150132375A1 (en) 2015-05-14
MX2019012939A (es) 2019-12-16
WO2011017502A9 (en) 2011-03-03
US20140287034A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
US8748573B2 (en) Formulations comprising linaclotide
US20230346881A1 (en) Stable Formulations of Linaclotide
JP7483656B2 (ja) リナクロチドの遅延放出組成物
CA2770334A1 (en) Orally disintegrating compositions of linaclotide
US20130012454A1 (en) Orally Disintegrating Compositions of Linaclotide
CA3048195A1 (en) Treatment methods and delayed release composition of linaclotide
US20230346878A1 (en) Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
US20250073301A1 (en) Delayed Release Compositions of Linaclotide
HK40017265A (en) Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150109

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150225